Corbus Pharmaceuticals Holdings, Inc. Net Income (Loss) Attributable to Noncontrolling Interest
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$78.54 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-03-09
- Corbus Pharmaceuticals Holdings, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2025 was -$78.54M.
- Corbus Pharmaceuticals Holdings, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2024 was -$40.21M.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|
| 2025-12-31 | -$78.54M 10-K · filed 2026-03-09 |
| 2024-12-31 | -$40.21M 10-K · filed 2026-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |